Neuroncell-EX not checked

Cytopeutics Sdn. Bhd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2/3 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Intravenous infusion of Neuroncell-EX (2 million UCMSCs per kg body weight) on day 1 and day 14 plus standard medical care.”In the company’s words, NCT06129175 on ClinicalTrials.gov
Tested for
Acute Ischemic Stroke
Main trialPhase 2/3
“The primary objective of this study is to evaluate the functional recovery based on Barthel index (BI) and modified Rankin Scale (mRS) while the secondary objectives are to assess the survival and re-admission rate as well as to investigate the inflammatory response in a subclinical study within 1 year of Neuroncell-EX infusion in participants with acute ischemic stroke.”In the company’s words, NCT06129175 on ClinicalTrials.gov

Other drugs for Acute Ischemic Stroke

All 45 drugs for Acute Ischemic Stroke

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 2/3Recruiting 30 Nov 2026 UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Neuroncell-EX

Following is part of Solo: you see every change to Neuroncell-EX the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in